Overall, this patient with mCRC harboring BRAF V600E mutation responded significantly after receiving triplet mFOLFOXIRI plus bevacizumab chemotherapy regimen, with an optimal response of 70% tumor reduction and achieved a PFS of 13 months. This evidence concerns the gene BRAF and neoplasm.